Veru Inc. VERU
2.31 USD +0.17 (+7.94%)
Regular-session close
2.33 +0.02 +0.73%
After hours · Nov 18, 4:00 PM ET
2.13 Day range 2.34
2.03 52-week range 7.33
- YTD
- +7.94%
- 1 year
- -8.70%
News
benzinga.com Veru Presents New Results At ObesityWeek; Adding Enobosarm Preserved Lean Mass And Stair Climb Physical Function In Older Patients ≥65 Years With Obesity Receiving Semaglutide Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of metabolic diseases and oncology, today announced that Veru had…
globenewswire.com Veru Presents New Results at ObesityWeek 2026: GLP-1 Weight Loss in Older Adults Associated with Physical Function Decline; Adding Enobosarm Preserved Significant Lean Mass and Physical Function -- In a post hoc analysis of patients ≥65 years from the positive Phase 2b QUALITY study, those on semaglutide + placebo lost significant lean mass and had reduced stair climb power and slower stair…benzinga.com Veru To Present Phase 2b QUALITY Study Analysis Of Physical Function In Older Obesity Patients At ObesityWeek 2026 Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of metabolic diseases and oncology, today announced Veru’s Chief…
